SCH-50911
SCH-50911，分子式C8H15NO3，是一種γ-氨基丁酸β受體（GABAB）選擇性拮抗劑[1]，用於治療酒精戒斷症候群中的震顫性譫妄而開發[2]。
| SCH-50911 | |
|---|---|
| |
| IUPAC名 2-[(2S)-5,5-Dimethylmorpholin-2-yl]acetic acid | |
| 識別 | |
| CAS號 | 160415-07-6 
|
| PubChem | 5311429 |
| ChemSpider | 4470917 |
| SMILES |
|
| InChI |
|
| InChIKey | SEYCKMQSPUVYEF-LURJTMIEBV |
| MeSH | SCH-50911 |
| IUPHAR配體 | 1075 |
| 性質 | |
| 化學式 | C8H15NO3 |
| 莫耳質量 | 173.21 g·mol⁻¹ |
| 熔點 | 154.5-157 °C（428-430 K）（鹽酸鹽） |
| 若非註明，所有數據均出自標準狀態（25 ℃，100 kPa）下。 | |
參考文獻
- ^ Blythin DJ, Kuo SC, Shue HJ, McPhail AT, Chapman RW, Kreutner W, et al. Substituted morpholine-2S-acetic acid derivatives: Sch 50911 and related compounds as novel GABAB antagonists.. Bioorganic & Medicinal Chemistry Letters. July 1996, 6 (13): 1529–34. doi:10.1016/S0960-894X(96)00267-3.
- ^ Quang LS, Colombo G, Lobina C, Maccioni P, Orru A, Gessa GL, et al. Evaluation for the withdrawal syndrome from gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines. Annals of the New York Academy of Sciences. August 2006, 1074: 545–58. PMID 17105952. doi:10.1196/annals.1369.055.